Patterson Companies ( (PDCO) ) just unveiled an update.
On April 22, 2025, Patterson Companies announced the completion of its acquisition by Patient Square Capital, a healthcare investment firm, which resulted in the company’s stock no longer being traded on the NASDAQ Global Select Market. Concurrently, Robert Rajalingam was appointed as the new CEO, succeeding Don Zurbay, who will continue to support the company during the transition. Rajalingam, with over 25 years of healthcare management experience, is expected to drive operational excellence and strategic growth, enhancing Patterson’s offerings and partnerships.
Spark’s Take on PDCO Stock
According to Spark, TipRanks’ AI Analyst, PDCO is a Neutral.
Patterson Companies scores well due to its stable operational efficiency and strong market momentum. However, challenges with profitability and cash flow management slightly dampen its overall performance. The stock’s valuation is fair, and its dividend yield is a positive aspect for investors seeking income. Technical indicators suggest strong momentum, though caution is advised due to potential overbought conditions.
To see Spark’s full report on PDCO stock, click here.
More about Patterson Companies
Patterson Companies Inc. is a leading supplier of products and services to the dental and animal health markets in North America and the U.K. The company connects its customers to the latest products, technologies, and innovative business solutions, supported by a comprehensive portfolio, distribution network, and dedicated customer service.
YTD Price Performance: 1.72%
Average Trading Volume: 1,647,450
Technical Sentiment Signal: Sell
Current Market Cap: $2.77B
Learn more about PDCO stock on TipRanks’ Stock Analysis page.